InvestorsHub Logo
icon url

Sully

02/19/09 2:43 PM

#9255 RE: Mr. Bill #9253

Go back to the Bank of America board. No interest in your garbage here. Plus, even in your post it states: "With 5-years of followup, all patients who achieved a major response (either complete or partial remission) on the
Genasense ® treatment arm achieved superior survival compared with responders treated with chemotherapy alone".

Get a clue.
icon url

TheReverend

02/19/09 2:49 PM

#9256 RE: Mr. Bill #9253

Your post make no sence MR. Bill you state Bad news and everything in your post is good news? maybe I am missing something?
icon url

STLCardinalsFan

02/19/09 3:09 PM

#9259 RE: Mr. Bill #9253

GREAT NEWS!!!

Phase 3/Chronic Lymphocytic Leukemia (CLL)/NDA Status : Genta has appealed a prior “non-approvable” decision on the Genasense ®
New Drug Application (NDA) for patients with relapsed/refractory CLL. The appeal is now pending a decision by FDA’s Center for Drug
Evaluation and Research (CDER). The pivotal randomized trial achieved its primary endpoint, which was to significantly increase the proportion
of patients who achieved complete remission by adding Genasense ® to standard chemotherapy compared with patients treated with
chemotherapy alone. With 5-years of followup, all patients who achieved a major response (either complete or partial remission) on the
Genasense ® treatment arm achieved superior survival compared with responders treated with chemotherapy alone. A decision from CDER is
expected in the current quarter.
icon url

JPGetty

02/20/09 3:22 AM

#9342 RE: Mr. Bill #9253

Just from reading that I would be inclined to say that Genasense is in! Approval is apt to follow. But that is just based on what you wrote there.